Dr. Peter J. Morrell, D.O.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 1,999
Licensed in Texas since 2007, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2006Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
TX license M8197 (first issued 2007; active) -
MOHS-Micrographic Surgery Physician
TX license M8197 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 1,999
- Services billed
- 8,464
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,487 | 333 |
| Established patient office or other outpatient visit, 10-19 minutes | 962 | 738 |
| Established patient office or other outpatient visit, 20-29 minutes | 763 | 601 |
| Biopsy of related skin growth, first growth | 648 | 581 |
| Destruction of skin growth, 1-14 growths | 582 | 526 |
| Destruction of precancer skin growth, 1 growth | 565 | 497 |
| New patient office or other outpatient visit, 15-29 minutes | 524 | 524 |
| New patient office or other outpatient visit, 30-44 minutes | 352 | 352 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 292 | 227 |
| Biopsy of related skin growth, each additional growth | 264 | 150 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 105 payments worth $2,066 in total to this clinician.
| AbbVie Inc. | $568 |
|---|---|
| Janssen Biotech, Inc. | $414 |
| Galderma Laboratories, L.P. | $258 |
| UCB, Inc. | $144 |
| Novartis Pharmaceuticals Corporation | $114 |
| Genzyme Corporation | $82.87 |
| Amgen Inc. | $79.78 |
| Incyte Corporation | $78.23 |
| Food and Beverage | $2,066 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.